The Food and Drug Administration approved on Friday the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older people.
The new drug, called Syfovre, is made by Apellis Pharmaceuticals.
Geographic atrophy is a disease of aging that occurs when the progressive formation of yellowish deposits under the retina damages and then destroys photoreceptors. The condition causes blind spots in vision that typically affect reading, driving, or night vision first, but eventually leads to blindness. Geographic atrophy affects 1 million people in the U.S. and another 2.7 million people in Europe.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
